Breaking Down SG&A Expenses: Johnson & Johnson vs Biogen Inc.

A Comparative Analysis of SG&A Expenses: Johnson & Johnson vs. Biogen Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Johnson & Johnson and Biogen Inc., from 2014 to 2023.

Key Insights

Over the past decade, Johnson & Johnson consistently outspent Biogen Inc. in SG&A expenses, with an average annual expenditure nearly ten times higher. In 2018, Johnson & Johnson peaked with expenses reaching approximately $22.54 billion, while Biogen's highest was around $2.67 billion in 2021. Notably, Biogen's expenses showed a steady increase, rising by about 32% from 2014 to 2023, reflecting strategic investments in marketing and administration.

Conclusion

This financial snapshot highlights the contrasting strategies of these companies, with Johnson & Johnson maintaining a robust expenditure to support its expansive operations, while Biogen Inc. demonstrates a more conservative approach.